Validation of the Refined ELN 2022 AML Risk Stratification Incorporating an Adverse-Plus Category and Impact on Allogeneic Transplant Outcome | Synapse
March 3, 2026
Validation of the Refined ELN 2022 AML Risk Stratification Incorporating an Adverse-Plus Category and Impact on Allogeneic Transplant Outcome
Key Points
Transplant outcomes improve with the incorporation of the adverse-plus category in risk stratification.
Overall survival rates were significantly enhanced for AML patients categorized under the refined model.
Assessment using data from multiple transplant centers highlights the importance of updated classification systems.
Findings imply that superior risk evaluation may lead to better therapy decisions for AML patients.